We are investigating possible false claims, accounting and reporting practices and breaches of fiduciary duty and violations of the federal securities laws by the Board of Directors and certain Company officers of CareDx, Inc. (NASDAQ: CDNA) (“CareDx” or the “Company”), which has led to investigations by the U.S. Department of Justice (“DOJ”) and the Securities and Exchange Commission (“SEC”) concerning “certain business practices related to [CareDx’s] kidney testing and phlebotomy services.”
On October 28, 2021, the Company filed a Form 10Q which disclosed that it had recently received a False Claims Act (“FCA”) civil investigative demand from the DOJ as well as a subpoena from the SEC related to the Company’s kidney testing and phlebotomy services “as well as certain of [CareDx’s] accounting and public reporting practices.” The Company also disclosed that an additional unnamed state regulatory agency has also made an information request, and it is possible that the Company will “receive additional requests for information from the DOJ, SEC, or other regulatory and governmental agencies regarding similar or related subject matters.”
WeissLaw LLP is investigating whether CareDx’s Board of Directors: failed to establish and maintain a comprehensive system of internal controls over certain of its kidney testing and phlebotomy services; failed to establish and maintain a comprehensive system of internal controls over its accounting and public reporting practices; and violated federal securities laws or breached fiduciary duties owed to CareDx and its shareholders.
If you own CDNA shares and wish to discuss this investigation, please visit our website at https://www.weisslaw.co/news-and-cases/cdna or contact Josh Rubin at firstname.lastname@example.org or (212) 682-3025. There is no cost or obligation to you.
WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties. We have recovered over a billion dollars for defrauded clients. For more information about the firm, please go to: http://www.weisslaw.co
November 15, 2021
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Dicerna Pharmaceuticals, Inc. (“Dicerna” or the “Company”) (NASDAQ: DRNA) in connection with the proposed acquisition of the Company by Novo Nordisk. Under the terms of the merger agreement, the Company’s shareholders will receive $38.25 per share in cash for each share of Dicerna common stock that they hold. The all-cash transaction is valued at $3.3 billion.
November 15, 2021
We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Patriot National Bancorp, Inc. (“Patriot National” or the “Company”) (NASDAQ: PNBK), in connection with the Company’s proposed merger with American Challenger Development Corp. (“American Challenger”) under which Patriot National will acquire American Challenger via a reverse subsidiary merger. Under the terms of the merger agreement, at the effective time of the merger, American Challenger common stockholders will receive shares of Patriot National common stock as consideration and American Challenger preferred stockholders will receive cash.
November 15, 2021
We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Casper Sleep Inc. (“Casper” or the “Company”) (NYSE:CSPR) in connection with the proposed acquisition of the Company by Durational Capital Management LP (“Durational”). Under the terms of the acquisition agreement, the Company’s shareholders will receive $6.90 per share in cash for each share of Casper common stock that they hold.